Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: Gazelle end of induction analysis
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Canales, Miguel A.
- dc.contributor.author Buchholz, Thomas A.
- dc.contributor.author Bortolini, Jaisson A. P.
- dc.contributor.author Fogliatto, Laura M.
- dc.contributor.author Ishikawa, Takayuki
- dc.contributor.author Izutsu, Koji
- dc.contributor.author Salar Silvestre, Antonio
- dc.contributor.author Sharman, Jeff P.
- dc.contributor.author Klingbiel, Dirk
- dc.contributor.author Pokala, Sunny
- dc.contributor.author Vorozheikina, Ekaterina
- dc.contributor.author Trask, Peter
- dc.contributor.author Parreira, Joana
- dc.contributor.author Hübel, Kai
- dc.date.accessioned 2024-03-07T07:11:50Z
- dc.date.available 2024-03-07T07:11:50Z
- dc.date.issued 2023
- dc.format.mimetype application/pdf
- dc.identifier.citation Canales MA, Buchholz TA, Bortolini JAP, Fogliatto LM, Ishikawa T, Izutsu K, Salar A, Sharman JP, Klingbiel D, Pokala S, Vorozheikina E, Trask P, Parreira J, Hübel K. Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: Gazelle end of induction analysis. Hemasphere. 2023 Mar 30;7(4):e860. DOI: 10.1097/HS9.0000000000000860
- dc.identifier.doi http://dx.doi.org/10.1097/HS9.0000000000000860
- dc.identifier.issn 2572-9241
- dc.identifier.uri http://hdl.handle.net/10230/59340
- dc.language.iso eng
- dc.publisher Wolters Kluwer (LWW)
- dc.relation.ispartof Hemasphere. 2023 Mar 30;7(4):e860
- dc.rights © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.other Anticossos monoclonals
- dc.subject.other Rituximab
- dc.title Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: Gazelle end of induction analysis
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion